Masaya Baba

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4937310/publications.pdf

Version: 2024-02-01

62 papers	3,977 citations	126708 33 h-index	128067 60 g-index
62 all docs	62 docs citations	62 times ranked	3976 citing authors

#	Article	IF	Citations
1	Seventh BHD international symposium: recent scientific and clinical advancement. Oncotarget, 2022, 13, 173-181.	0.8	4
2	Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamideâ€“chlorambucil conjugate. Cancer Science, 2022, 113, 2352-2367.	1.7	3
3	Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. IScience, 2022, 25, 104463.	1.9	4
4	t(6; 11) renal cell carcinoma. A case report successfully diagnosed by using fluorescence in situ hybridization. IJU Case Reports, 2021, 4, 375-378.	0.1	1
5	FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. Biochemical and Biophysical Research Communications, 2020, 522, 931-938.	1.0	5
6	Establishment of bone marrow-derived M-CSF receptor-dependent self-renewing macrophages. Cell Death Discovery, 2020, 6, 63.	2.0	18
7	Blood and lymphatic systems are segregated by the FLCN tumor suppressor. Nature Communications, 2020, 11, 6314.	5.8	17
8	A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity. Cell Reports, 2020, 30, 1823-1834.e5.	2.9	18
9	Folliculin Interacting Protein 1 Maintains Metabolic Homeostasis during B Cell Development by Modulating AMPK, mTORC1, and TFE3. Journal of Immunology, 2019, 203, 2899-2908.	0.4	10
10	MicroRNAâ€204â€5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. Cancer Science, 2019, 110, 1897-1908.	1.7	55
11	TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease. Molecular Cancer Research, 2019, 17, 1613-1626.	1.5	35
12	RBM10â€“TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in breakâ€apart fluorescence inâ€situ hybridisation: study of 10 cases and a literature review. Histopathology, 2019, 75, 254-265.	1.6	29
13	Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. Genes and Development, 2019, 33, 1641-1656.	2.7	9
14	Editorial Comment to AnnexinÂA1 expression is correlated with malignant potential of renal cell carcinoma. International Journal of Urology, 2019, 26, 291-291.	0.5	1
15	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Human Molecular Genetics, 2018, 27, 2712-2724.	1.4	14
16	Splice-site mutation causing partial retention of intron in the FLCN gene in Birt-Hogg-DubÃ© syndrome: a case report. BMC Medical Genomics, 2018, 11, 42.	0.7	10
17	Folliculin Regulates Osteoclastogenesis Through Metabolic Regulation. Journal of Bone and Mineral Research, 2018, 33, 1785-1798.	3.1	21
18	Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birtâ€“Hoggâ€“DubÃ© syndrome. Laboratory Investigation, 2017, 97, 343-351.	1.7	2

#	Article	IF	Citations
19	Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors. Polish Journal of Pathology, 2017, 68, 284-290.	0.1	5
20	Hereditary Renal Cell Carcinoma. , 2017, , 19-82.		1
21	Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. Stem Cells, 2016, 34, 1068-1082.	1.4	25
22	Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birtâ€“Hoggâ€“DubÃ© syndrome. Clinical Genetics, 2016, 90, 403-412.	1.0	80
23	H255Y and K508R missense mutations in tumour suppressorfolliculin (FLCN)promote kidney cell proliferation. Human Molecular Genetics, 2016, 26, ddw392.	1.4	17
24	Chronic AMPK activation via loss of FLCN induces functional beige adipose tissue through PGC-1Î±/ERRÎ±. Genes and Development, 2016, 30, 1034-1046.	2.7	83
25	Birtâ€“Hoggâ€“DubÃ© syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome. International Journal of Urology, 2016, 23, 204-210.	0.5	46
26	Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1624-31.	3.3	74
27	Folliculin Controls Lung Alveolar Enlargement and Epithelial Cell Survival through E-Cadherin, LKB1, and AMPK. Cell Reports, 2014, 7, 412-423.	2.9	84
28	Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. Human Molecular Genetics, 2014, 23, 5706-5719.	1.4	54
29	Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN. Journal of the National Cancer Institute, 2012, 104, 1750-1764.	3.0	82
30	The folliculin-FNIP1 pathway deleted in human Birt-Hogg-DubÃ© syndrome is required for murine B-cell development. Blood, 2012, 120, 1254-1261.	0.6	57
31	Identification of intragenic deletions and duplication in the FLCN gene in Birtâ€Hoggâ€DubÃ© syndrome. Genes Chromosomes and Cancer, 2011, 50, 466-477.	1.5	50
32	Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-Î² signaling. Molecular Cancer, 2010, 9, 160.	7.9	81
33	Inactivation of the FLCN Tumor Suppressor Gene Induces TFE3 Transcriptional Activity by Increasing Its Nuclear Localization. PLoS ONE, 2010, 5, e15793.	1.1	146
34	Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18722-18727.	3.3	203
35	A threeâ€gene expression signature model to predict clinical outcome of clear cell renal carcinoma. International Journal of Cancer, 2008, 123, 1126-1132.	2.3	46
36	Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene, 2008, 415, 60-67.	1.0	163

#	Article	IF	Citations
37	Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys. Journal of the National Cancer Institute, 2008, 100, 140-154.	3.0	223
38	Identification and characterization of Birtâ€“Hoggâ€“DubÃ© associated renal carcinoma. Journal of Pathology, 2007, 211, 524-531.	2.1	45
39	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15552-15557.	3.3	427
40	Detection of germline deletions using real-time quantitative polymerase chain reaction in Japanese patients with von Hippel-Lindau disease. Cancer Science, 2006, 97, 400-405.	1.7	19
41	Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Laboratory Investigation, 2006, 86, 664-675.	1.7	25
42	Inactivation of von Hippel-Lindau Gene Induces Constitutive Phosphorylation of MET Protein in Clear Cell Renal Carcinoma. Cancer Research, 2006, 66, 3699-3705.	0.4	89
43	Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. Journal of Pathology, 2005, 205, 377-387.	2.1	166
44	Acidic Extracellular pH Induces Matrix Metalloproteinase-9 Expression in Mouse Metastatic Melanoma Cells through the Phospholipase D-Mitogen-activated Protein Kinase Signaling. Journal of Biological Chemistry, 2005, 280, 10938-10944.	1.6	145
45	Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Oncology Reports, 2005, 13, 1033-41.	1.2	10
46	Transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson's disease. Annals of Neurology, 2003, 54, 352-359.	2.8	28
47	Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor. Oncogene, 2003, 22, 2728-2738.	2.6	97
48	Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Research, 2003, 63, 5320-8.	0.4	94
49	VHL Tumor Suppressor Gene Alterations Associated With Good Prognosis in Sporadic Clear-Cell Renal Carcinoma. Journal of the National Cancer Institute, 2002, 94, 1569-1575.	3.0	216
50	Comprehensive mutational analysis of theVHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes and Cancer, 2002, 34, 58-68.	1.5	197
51	Von Hippel-Lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells. Cancer Research, 2002, 62, 7004-11.	0.4	22
52	Induction of SPARC by VEGF in Human Vascular Endothelial Cells. Biochemical and Biophysical Research Communications, 2001, 287, 422-426.	1.0	54
53	SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma. Human Pathology, 2001, 32, 1064-1070.	1.1	50
54	PTENMMAC1TEP1 mutations in human primary renalâ€cell carcinomas and renal carcinoma cell lines. International Journal of Cancer, 2001, 91, 219-224.	2.3	83

#	Article	IF	Citations
55	Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth. Oncogene, 2001, 20, 2727-2736.	2.6	46
56	The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C. Journal of Biological Chemistry, 2001, 276, 43611-43617.	1.6	161
57	Bilateral testicular tumors in androgen insensitivity syndrome. International Journal of Urology, 2000, 7, 390-392.	0.5	31
58	Germ-line Mutation Analysis in Patients with von Hippel-Lindau Disease in Japan: An Extended Study of 77 Families. Japanese Journal of Cancer Research, 2000, 91, 204-212.	1.7	45
59	MAPK Upstream Kinase (MUK)-binding Inhibitory Protein, a Negative Regulator of MUK/Dual Leucine Zipper-bearing Kinase/Leucine Zipper Protein Kinase. Journal of Biological Chemistry, 2000, 275, 21247-21254.	1.6	46
60	Direct Interaction of the Î²-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes. Biochemical and Biophysical Research Communications, 1999, 263, 491-497.	1.0	86
61	Stimulation of Motility of Human Renal Cell Carcinoma by SPARC/Osteonectin/BM-40 Associated with Type IV Collagen. Invasion & Metastasis, 1998, 18, 105-114.	0.5	18
62	Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Oncology Reports, 0, , .	1.2	1